| Identification | |
| Name: | Leuprorelin acetate |
| Synonyms: | (D-Leu(sup 6),des-gly-NH2(sup 10),pro-ethylamide(sup 9))-LHRH;Lupron;Leuprolide acetate (USAN);Abbott 43818;Lupron Depot;TAP-144-SR;Leuprorelin acetate (JAN);Lupron PED;Leuprin;acetic acid; N-[(1S)-1-[[(1S)-1-[[1-[[(1S)-1-[[(1R)-1-[[(1S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxo-pentan-2-yl]carbamoyl]-2-methyl-propyl]carbamoyl]-2-methyl-propyl]carbamoyl]-2-(4-hydroxyphenyl)ethyl]carbamoyl]-2-hydroxy-ethyl]carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl]-2-(3H-imidazol-4-yl)ethyl]-5-oxo-pyrrolidine-2-carboxamide;Procrin;A-43818;Leuproreline [INN-French];Eligard;Leuplin depot;TAP 144;Leuprorelinum [INN-Latin];Depo-Lupron;Viadur;Lucrin;TAP-144;Uno-Enantone;Procren Depot;Leuprorelina [INN-Spanish];Leuprolide acetate [USAN];(D-Leu(sup 6),des-gly-NH2(sup 10),pro-ethylamide(sup 9))-gonadotropin-releasing hormone; |
| CAS: | 74381-53-6 |
| Molecular Formula: | C59H84N16O12.C2H4O2 |
| Molecular Weight: | 1269.45 |
| InChI: | InChI=1/C57H80N16O12.C2H4O2/c1-6-61-53(82)44-14-10-22-73(44)56(85)39(13-9-21-62-57(58)59)66-54(83)46(30(2)3)72-55(84)47(31(4)5)71-51(80)40(23-32-15-17-35(75)18-16-32)67-52(81)43(28-74)70-49(78)41(24-33-26-63-37-12-8-7-11-36(33)37)68-50(79)42(25-34-27-60-29-64-34)69-48(77)38-19-20-45(76)65-38;1-2(3)4/h7-8,11-12,15-18,26-27,29-31,38-44,46-47,63,74-75H,6,9-10,13-14,19-25,28H2,1-5H3,(H,60,64)(H,61,82)(H,65,76)(H,66,83)(H,67,81)(H,68,79)(H,69,77)(H,70,78)(H,71,80)(H,72,84)(H4,58,59,62);1H3,(H,3,4)/t38?,39-,40-,41-,42-,43?,44-,46-,47+;/m0./s1 |
| Molecular Structure: |  |
| Properties | |
| Appearance: | fluffy solid |
| Specification: | Fluffy Solid usageEng:Synthetic nonapeptide agonist analog of LH-RH. Antineoplastic (hormonal). Safety Statements:22-24/25 22:Do not breathe dust 24/25:Avoid contact with skin and eyes |
| Usage: | Synthetic nonapeptide agonist analog of LH-RH. Antineoplastic (hormonal). |
| Safety Data | |
| Hazard Symbols | |
 |
|
